****Pfizer Q1 2026 results and earnings-call transcript** [developing]** [developing]
Key Questions
What were Pfizer's Q1 2026 earnings per share and revenue figures?
Pfizer reported Q1 EPS of $0.77, down 16% year-over-year, and revenue of $17.56 billion, up 0.9% YoY and beating estimates by 4%. These results were announced on March 13, 2026.
What is Pfizer's full-year 2026 guidance?
Pfizer guided FY26 revenue at $59.5-62.5 billion, roughly flat year-over-year, with FY EPS around $2.97, aligning closely with consensus estimates of $2.96 EPS.
Why did Pfizer's stock drop despite beating earnings estimates?
Pfizer's stock closed at $27.10, down 2.62% on April 7, with after-hours at $27.42 amid heavy volume and bearish options activity (PCR 1.11, IV 26.96). Analysts like RBC maintained a $25 price target, citing concerns despite the beats.
What is Pfizer's current dividend yield and associated risks?
Pfizer offers a 6.74% dividend yield with a 100% payout ratio, facing risks from $17 billion in looming patent expirations (LOE). Investors are attracted to the steady return amid uncertainty.
What recent deals or cash inflows did Pfizer announce?
Pfizer secured $1.875 billion cash from ViiV exit, $2.2 billion from Belgium, and €1.9 billion from EU for COVID-related payments. These bolstered its financial position.
What cost-saving measures is Pfizer implementing in 2026?
Pfizer anticipates $5.7 billion in savings for 2026. This includes closing its South San Francisco Oyster Point site by end-April.
How do analysts rate Pfizer stock post-Q1 results?
Consensus price target is $28.52 with a Hold rating; Guggenheim at $36, Morningstar $38, but RBC at $25 Underperform. Institutional flows remain positive.
When is Pfizer's next earnings call?
Pfizer's Q2 earnings are scheduled for May 5, 2026.
Pfizer Q1 EPS $0.77 (−16% YoY), revenue $17.56B (+0.9% YoY +4% surprise) 2026-03-13; FY EPS ~$2.97, FY26 rev $59.5-62.5B flat/ EPS $2.96 est; ViiV exit $1.875B cash. Abrysvo RSV NHS 3M adults 80+; SSF Oyster Point closure end-April; Belgian $2.2B + EU €1.9B COVID; $5.7B savings '26; organic rev 10.1% YoY avg 2yrs, op margin 35.1% TTM; stock $27.10 -2.62% Apr7 close/AH $27.42 heavy vol/bearish options puts PCR 1.11 IV 26.96 incl 36,700 $24 puts/RBC $25 PT tumbles despite beats; 6.74% div yield/100% payout risk/LOE $17B; inst flows +; Trump exemptions; Guggenheim $36/Morningstar $38/cons $28.52; Q2 May 5.